Use of lipid conjugates in the treatment of disease
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorSaul Yedgar
Life of this patent
Estimating the term…
Abstract
This invention provides a method of preventing asthma, allergic rhinitis, or chronic obstructive pulmonary disease in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating allergic rhinitis or chronic obstructive pulmonary disease in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
Claims54
A method of decreasing the number or frequency of relapse episodes or reducing the incidence of disease-related symptoms of asthma in a subject, comprising the step of administering to a subject a compound represented by the structure of the general formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is a glycosaminoglycan;
- and 2 to 200;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of treating a subject suffering from allergic rhinitis, comprising the step of administering to a compound represented by the structure of the general formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of decreasing the number or frequency of relapse episodes or reducing the incidence of disease-related symptoms of allergic rhinitis in a subject, comprising the step of administering to a subject a compound of formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of treating a subject suffering from chronic obstructive pulmonary disease, comprising the step of administering to a subject a compound of formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of decreasing the number or frequency or reducing the incidence of disease-related symptoms of chronic obstructive pulmonary disease in a subject, comprising the step of administering to a subject a compound represented by the structure of the general formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of delaying the onset of symptoms of asthma in a subject, comprising the step of administering to a subject a compound represented by the structure of the general formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of delaying the onset of symptoms of allergic rhinitis in a subject, comprising the step of administering to a subject a compound represented by the structure of the general formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of delaying the onset of symptoms of chronic obstructive pulmonary disease in a subject, comprising the step of administering to a subject a compound represented by the structure of the general formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
A method of treating a subject suffering from asthma, comprising the step of administering to a subject a compound of formula I:
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- and
- X is a glycosaminoglycan;
- and
- n is a number 2 to 200;
- wherein said spacer comprises —CO-alkylene-NH—, —CO-alkylene-CO— or a combination thereof and said spacer is linked to a hydroxyl or carboxylic acid of said glycosaminoglycan;
- and wherein if Y is nothing the phosphatidylethanolamine is directly linked to glycosaminoglycane via a carboxylic group.
Dependencies are inferred from the claim text.